MRNA Moderna Inc

Price (delayed)

$310.61

Market cap

$125.94B

P/E Ratio

17.7

Dividend/share

N/A

EPS

$17.55

Enterprise value

$120.73B

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights
The net income has soared by 102% from the previous quarter
The company's EPS has surged by 102% QoQ
The debt has surged by 65% year-on-year but it has declined by 21% since the previous quarter
The quick ratio has contracted by 49% YoY but it has grown by 7% from the previous quarter
The gross margin has contracted by 14% YoY

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
405.45M
Market cap
$125.94B
Enterprise value
$120.73B
Valuations
Price to earnings (P/E)
17.7
Price to book (P/B)
12.38
Price to sales (P/S)
10.61
EV/EBIT
15.88
EV/EBITDA
15.42
EV/Sales
10.2
Earnings
Revenue
$11.83B
EBIT
$7.6B
EBITDA
$7.83B
Free cash flow
$11.39B
Per share
EPS
$17.55
Free cash flow per share
$28.19
Book value per share
$25.08
Revenue per share
$29.28
TBVPS
$51.79
Balance sheet
Total assets
$20.92B
Total liabilities
$10.8B
Debt
$343M
Equity
$10.12B
Working capital
$3.47B
Liquidity
Debt to equity
0.03
Current ratio
1.35
Quick ratio
1.21
Net debt/EBITDA
-0.67
Margins
EBITDA margin
66.2%
Gross margin
85.9%
Net margin
59.7%
Operating margin
64.3%
Efficiency
Return on assets
49.5%
Return on equity
121.6%
Return on invested capital
406.7%
Return on capital employed
69.3%
Return on sales
64.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
-11.87%
1 week
13.61%
1 month
-7.88%
1 year
120.28%
YTD
197.32%
QTD
-19.29%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$11.83B
Gross profit
$10.16B
Operating income
$7.61B
Net income
$7.06B
Gross margin
85.9%
Net margin
59.7%
Moderna's operating margin has surged by 126% YoY and by 18% QoQ
The net margin has surged by 125% year-on-year and by 20% since the previous quarter
The net income has soared by 102% from the previous quarter
The operating income has soared by 99% from the previous quarter

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
P/E
17.7
P/B
12.38
P/S
10.61
EV/EBIT
15.88
EV/EBITDA
15.42
EV/Sales
10.2
The company's EPS has surged by 102% QoQ
The equity has soared by 51% QoQ
MRNA's P/B is 16% below its last 4 quarters average of 14.8
MRNA's revenue has soared by 69% since the previous quarter
The stock's P/S is 55% below its last 4 quarters average of 23.8

Efficiency

How efficient is Moderna business performance
The company's return on sales has surged by 127% YoY and by 18% QoQ
Moderna's ROA has increased by 45% from the previous quarter
MRNA's return on equity is up by 38% since the previous quarter
The ROIC has contracted by 4.3% from the previous quarter

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
Moderna's total assets is 94% more than its total liabilities
The quick ratio has contracted by 49% YoY but it has grown by 7% from the previous quarter
The current ratio has declined by 44% year-on-year but it is up by 9% since the previous quarter
The debt is 97% smaller than the equity
The debt has surged by 65% year-on-year but it has declined by 21% since the previous quarter
The company's debt to equity has shrunk by 63% YoY and by 50% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.